Fujian South Pharmaceutical Co. Ltd · 66-66 · CHINA
For Fujian South Pharmaceutical Co. Ltd · 66-66 · CHINA, import alert is 66-66; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; country is CHINA; product is Paclitaxel; product code is 62 I - - 91 Paclitaxel (Anti-Neoplastic); date published is 08/14/2012; address is Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA, verified against its source on 2026-09-16.
- Firm
- Fujian South Pharmaceutical Co. Ltd verified
- Import alert
- 66-66
- Import alert name
- "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
- Country
- CHINA verified
- Address
- Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA verified
- Date published
- 08/14/2012 verified
- Product code
- 62 I - - 91 Paclitaxel (Anti-Neoplastic) verified
- Product
- Paclitaxel verified
What the source says
Fujian South Pharmaceutical Co. Ltd Date Published : 08/14/2012 Mingxi County , No. 98 Dongxin Road; Xuefengzhen Mingxixian , Sanming, Fujian CHINA 62 I - - 91 Paclitaxel (Anti-Neoplastic) Date Published: 08/14/2012 Desc: Paclitaxel
— accessdata.fda.gov, retrieved 2026-09-15
Source
- accessdata.fda.govhttps://www.accessdata.fda.gov/cms_ia/importalert_202.html
This one changes, and we watch it.FDA import alert red lists: firms subject to detention without physical examination is re-read on a schedule and every change is dated. Subscribe: Atom feed · JSON · what has changed so far.